|
||||
|
Felix Salmon discusses a new study out of the IESE Business School in Madrid that discusses the value destroyed by S&P 500 component companies which issued shares at peak levels. In the period 1991-2010, the S&P 500 destroyed value for the shareholders ($4.5 trillion). In 1991-1999 it created value ($5.1 trillion), but in 2000-2010 it destroyed $9.6 trillion. The market value of the S&P 500 was $2.8 trillion in 1991 and $11.4 trillion in 2010. We . . . Mark Mobius, Vice-Chairman of Franklin Templeton Investments recently wrote the following in support of emerging market small-cap companies. Small-cap companies in emerging markets are generally under-researched and not as established as their large-cap counterparts. Some have very short track records, not much background and little publicly accessible information, therefore presenting a higher level of perceived risk and deterring many investors. But for these very reasons, share prices of small–cap companies are less likely to reflect their true value with fewer . . . Quick follow up on a company I reviewed two weeks ago, International Lottery & Totalizator Systems (OTC:ITSI). Yesterday was a great day for anyone that was able to get in (remember, it has extremely low volume), with the stock jumping up 59.09% on 27x average volume. Pretty impressive! Keep in mind that this company has massive volatility (likely the result of such low volume and a low share price), so an opportunity might present itself again! . . . NYTimes has a nice visual representation of the proposed budget. Green means increases in spending, red means decreases.
Check out the full size version here Last month I discussed Celegene Corp’s Contingent Value Rights (CVRs) here and here. The Wall Street Journal ran a story today that shows all of the pharmaceutical transactions in the past ten years to use CVRs: Celgene’s 2010 purchase of Abraxis Bioscience Ligand’s 2010 purchase of Metabasis Therapeutics Ligand’s 2009 purchase of Neurogen Endo’s 2009 purchase of Indevus Pharmaceuticals Medicines Co.’s 2009 purchase of Targanta Therapeutics Ligand’s 2008 purchase of Pharmacopeia Fresenius SE’s 2008 purchase of . . . |
About Frank Voisin Subscribe for free updates:
 |
|||
|
Copyright © 2013 Frank Voisin. All Rights Reserved. Content may not be copied, distributed, re-transmitted, or re-posted in any form without prior approval. Any quotes must include credit to the author including a link to the original source. The information found on this site should not be considered to be investment advice. Any investment decisions you make should be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs. The author is not a registered investment advisor and does not represent the information on this site as a recommendation for readers to buy or sell the securities under discussion. All information contained herein is believed to be accurate at the time the information is posted. However, it is possible that errors may exist on this site. The reader should conduct his or her own due diligence and not, under any circumstances, rely on any of the information presented on this site. All liability for the content of this website, including any omissions, inaccuracies, errors, or misstatements is expressly disclaimed. Always complete your own due diligence. The author will disclose positions held in securities under discussion at the time of posting, however the author will NOT update prior posts or otherwise communicate changes in market positions after the time of posting. Powered by WordPress & Atahualpa |
||||
